How does ibogaine work on opioid withdrawal specifically?

Ibogaine acts as a partial agonist at the mu-opioid receptor — the same receptor opioids bind to. This interrupts the physical withdrawal process within hours, rather than allowing it to build over days. At the same time, GDNF upregulation begins restoring dopamine pathway function depleted by long-term opioid use. Physical cravings are typically absent or substantially reduced in the days after ceremony. This is a different mechanism from substitution therapies like methadone or buprenorphine. Methadone specifically is an absolute contraindication for ibogaine and requires a supervised transition protocol before any ceremony date can be set.

What is the difference between ibogaine and noribogaine?

Ibogaine is the primary alkaloid from Tabernanthe iboga root bark — the compound that produces the 12–24 hour active experience. Noribogaine is ibogaine's main active metabolite, produced as ibogaine is processed by the liver. Noribogaine remains pharmacologically active for weeks to months after ceremony, producing a sustained anxiolytic and neuroplastic effect without the psychedelic intensity of the parent compound. This extended metabolite activity is the mechanism behind ibogaine's long-term effects — the window during which integration work has the most leverage.

How is ibogaine administered at a legitimate ceremony?

Oral administration — typically as whole-plant root bark containing ibogaine plus additional alkaloids, or as isolated ibogaine HCl. A legitimate programme includes pre-ceremony medical screening completed and reviewed before any ceremony date is set, a physician physically present on-site for the full duration of the active experience, continuous cardiac ECG monitoring throughout, and a supervised 2–3 day recovery period. A flood dose is the typical therapeutic administration — given once, not repeatedly. Dosing is weight-adjusted and determined by the medical team based on screening results.

Does ibogaine work for people who haven't tried other treatments first?

This is not the first question to ask. The first question is whether a specific person is medically appropriate — which requires screening before any consideration of sequencing. That said, the population with the strongest clinical evidence is treatment-resistant: people for whom conventional approaches were not sufficient. Someone seeking ibogaine as a first-line treatment for a condition that has not been evaluated or treated conventionally is unlikely to be an appropriate candidate at this point. The intake conversation is where this is determined for a specific individual.

What medications cannot be combined with ibogaine?

Absolute contraindications include: SSRIs and SNRIs (serotonin syndrome risk — real and potentially fatal, no exceptions); lithium; methadone without a supervised transition protocol; most antipsychotics; prescription MAOIs; tramadol. SSRIs require a physician-supervised taper completed before ceremony — typically 2–4 weeks, longer for medications with extended half-lives such as fluoxetine. These are hard contraindications, not cautions to weigh against potential benefit. A complete medication review is a required part of pre-ceremony screening.

What does ibogaine do to your brain long-term?

The long-term neurological research is ongoing. GDNF upregulation from a single ibogaine ceremony appears to produce durable restoration in dopamine pathway function — the proposed mechanism for sustained addiction remission. Noribogaine sustains elevated neuroplasticity for weeks to months. What is consistently observed in practice is that one-year outcomes depend heavily on what was done during the weeks following ceremony — the window that noribogaine creates is not self-executing. Structured integration work during that period produces consistently better outcomes than returning to an unchanged environment without support.

Who should not take ibogaine?

Absolute contraindications: QT prolongation or significant cardiac arrhythmia on EKG; recent myocardial infarction; current SSRIs or SNRIs without a completed physician-supervised taper (potentially fatal serotonin syndrome risk — no exceptions); lithium; methadone without a completed transition protocol; most antipsychotics; severe liver or kidney disease; active psychosis or schizophrenia-spectrum disorder; and pregnancy. Someone in acute psychiatric crisis — active suicidality, active psychosis, recent psychiatric hospitalisation — is not an appropriate candidate at this time regardless of how long they have been searching for something that works.

Is ibogaine's mechanism fully understood by science?

No. The receptor binding profile — mu-opioid partial agonism, serotonin transporter inhibition, NMDA antagonism, GDNF upregulation — is well-documented. How these mechanisms interact to produce the specific outcomes the Stanford study recorded is an active area of research. The $50 million committed to clinical trials at four Texas institutions is partly aimed at answering this. An incompletely understood mechanism does not change the clinical findings: 88% PTSD symptom reductions at one month in 30 treatment-resistant veterans are not explained by placebo, regardless of how precisely the mechanism is mapped.

How Does Ibogaine Work? The Mechanism, the Experience, and Who It Is Not For

How ibogaine works is a precise question with a precise answer. It binds to four receptor systems simultaneously — mu-opioid receptors, the serotonin transporter, NMDA receptors, and sigma-2 receptors — and triggers upregulation of GDNF, a neuroplasticity protein depleted in addiction-affected, PTSD-affected, and depression-affected brain pathways. No approved medication does all of these at once. The 2023 Stanford study found 88% reductions in PTSD symptoms, 87% in depression, and 81% in anxiety at one month in 30 special operations veterans who had already exhausted conventional treatment. The 12–24 hour active experience is followed by weeks of elevated neuroplasticity through noribogaine, ibogaine's active metabolite. Whether that window produces lasting change depends entirely on what happens after ceremony.

Ibogaine acts on mu-opioid receptors, the serotonin transporter, NMDA receptors, and GDNF pathways simultaneously. The Stanford study found 88% PTSD reductions, 87% depression reductions, and 81% anxiety reductions at one month in 30 treatment-resistant veterans. The active experience runs 12–24 hours. The noribogaine metabolite remains active for weeks to months. SSRIs and SNRIs — the most common first-line treatment for the conditions ibogaine addresses — are absolute contraindications.

What Ibogaine Binds To — The Receptor Profile

Most psychiatric medications act on one receptor system. Ibogaine acts on four simultaneously, which is what makes its mechanism distinct from anything currently approved.

Mu-opioid receptors. Ibogaine is a partial agonist at the mu-opioid receptor — the same receptor that opioids bind to. This is why opioid withdrawal stops within hours of ibogaine administration rather than building over days. People in active opioid dependence describe withdrawing symptoms ceasing during the onset of the experience. It is not a substitution therapy. It is not providing a controlled opioid. It is acting on the receptor at a level that interrupts the withdrawal cascade without producing ongoing dependence.

The serotonin transporter (SERT).Ibogaine inhibits the serotonin transporter — the same protein SSRIs act on. This is the mechanism behind one of ibogaine's most consequential contraindications: combining ibogaine with a serotonergic medication creates conditions for serotonin syndrome. The risk is real and potentially fatal. SSRIs and SNRIs are absolute contraindications for ibogaine, not relative risks to weigh. No exception exists.

NMDA receptors. Ibogaine acts as an NMDA receptor antagonist — it interrupts glutamate transmission patterns that maintain anxiety responses and entrenched neurological habits. This is mechanistically related to how ketamine works for treatment-resistant depression. The qualitative character of the experience and its duration are entirely different, but the receptor-level disruption of fixed patterns is a shared mechanism.

GDNF upregulation.This is the mechanism that extends ibogaine's effect well beyond the active experience. More detail in the section below.

More on what these receptor interactions mean for the subjective experience is in the post on what ibogaine does to the brain.

The GDNF Factor — Why Ibogaine Is Neurologically Distinct

GDNF — glial cell line-derived neurotrophic factor — is a protein responsible for the survival and function of dopamine neurons. It is depleted in the reward and stress pathways of people with opioid use disorder, severe PTSD, and treatment-resistant depression.

Ibogaine appears to trigger GDNF upregulation at levels no approved antidepressant or addiction medication achieves. This is documented in multiple papers indexed on PubMed and referenced in the Stanford study published in Nature Medicine. The restoration of dopamine pathway function is the proposed mechanism for why craving is substantially reduced in the weeks following ceremony — a reduction that is not explained by the acute experience alone.

BDNF — brain-derived neurotrophic factor — is also upregulated by ibogaine. BDNF is involved in synaptic plasticity and the formation of new neurological patterns. Together, GDNF and BDNF upregulation create a neuroplasticity window — a period during which existing patterns are more accessible to change than they would otherwise be. This window continues through the weeks of noribogaine activity after ceremony. The integration period is not a post-script to the active experience. It is when the work is possible.

What the 12–24 Hour Experience Involves

The active experience is described consistently enough across accounts that its general shape is reliable, even if the specific content is individual.

Onset typically begins within one to three hours of administration. The first hours are physically demanding: tinnitus is nearly universal, ataxia makes standing without support difficult, and closed-eye visuals are present. Nausea is common in the early phase. This is not the experience most people imagine when they first research ibogaine — and it is not described adequately by any account that does not include these elements.

The psychedelic content is biographical rather than symbolic. Not geometric patterns or archetypal imagery — specific memories, specific relationships, the pattern of decisions a person has made and the events that shaped those decisions. The emotional charge that would normally accompany a review of painful material is reduced. People describe encountering difficult content with something closer to clarity than to the emotional distance of suppression.

The medicine does not deliver what people come hoping for. It delivers what is present. The people who arrive expecting a certain kind of experience — a spiritual shortcut, a relief from the weight of what they have been carrying — tend to find the medicine does not accommodate that expectation. What iboga consistently shows people is what they have been avoiding, not what they came hoping to find. The people who get the most from ceremony are usually the ones who arrived knowing the other options had not been enough.

Details on each phase of the experience — onset, peak, resolution, and the residual period — are in the post on the ibogaine experience.

The Noribogaine Window

Noribogaine is ibogaine's primary active metabolite. It is produced as the liver processes ibogaine and remains pharmacologically active for weeks to months after a single ceremony — substantially longer than the active metabolite of any other plant medicine in clinical use.

During the noribogaine window, craving is reduced, the neuroplasticity effects of the parent compound persist at a lower intensity, and new patterns are more accessible to establish than they would otherwise be. This is the mechanism that makes integration not optional: the ceremony opens a window, and the window does not stay open indefinitely.

People who return immediately to the same environment, relationships, and unaddressed conditions that produced their presenting problem tend to find the change does not hold. The experience surfaces the material. The weeks that follow determine what is done with it. Providers who hand participants a pamphlet at departure and wish them luck are not providing ibogaine treatment — they are providing ibogaine. Integration support is what converts the neuroplasticity window into lasting change.

What the integration period looks like in practice is covered in the integration programme.

What the Stanford Study Found

The 2023 Stanford study published in Nature Medicine examined ibogaine in 30 male special operations veterans with treatment-resistant PTSD, traumatic brain injury, or both — people for whom conventional treatment had not worked. This was not a naive population. They had evidence that the available options were insufficient.

At one month post-treatment:

PTSD symptoms: 88% average reduction
Depression symptoms: 87% average reduction
Anxiety symptoms: 81% average reduction

For context: conventional antidepressant research considers a 50% reduction in depression scores a strong response. The Stanford numbers are in a different category.

The study has real limitations. 30 participants is not a definitive population. There is no placebo arm. These are genuine methodological limitations, not caveats to minimise. The numbers are compelling enough to stand with them included — and the $50 million committed to follow-up clinical trials at UTMB, UTHealth Houston, Texas A&M, and Baylor suggests institutional medicine has read the findings the same way.

The full mechanism behind these results is not completely understood. The receptor profile explains why opioid withdrawal stops. GDNF restoration explains why the effects extend beyond the active experience. The specific interaction between ibogaine's mechanisms and the PTSD symptom complex is an active area of research. MAPS (Multidisciplinary Association for Psychedelic Studies) maintains a research database covering ibogaine across multiple populations and treatment contexts.

More detail on the Stanford findings is in the post on ibogaine for depression.

Who Ibogaine Is Not For

This section matters more than the mechanism above. The following are not risks to weigh — they are conditions under which ibogaine cannot be administered safely.

Cardiac contraindications. Ibogaine extends the cardiac QT interval for the duration of the active experience. In people with undetected QT prolongation, significant cardiac arrhythmia, or recent myocardial infarction, this is the mechanism that has caused deaths when screening was skipped. A pre-ceremony 12-lead EKG identifies this contraindication. No amount of interest in the medicine makes it safe to proceed without one. Any provider who skips cardiac screening is not operating safely — this is not a policy preference, it is basic pharmacology.

Current SSRIs or SNRIs. The most common contraindication in the population that wants ibogaine — because the most common conventional treatment for PTSD and depression is an SSRI, and the people who find ibogaine tend to be the people for whom SSRIs have not worked. Ibogaine inhibits the serotonin transporter. Combining it with serotonergic medications creates conditions for serotonin syndrome, which can be fatal. A completed, physician-supervised taper is required before ceremony. No exceptions.

Other absolute contraindications. Lithium. Methadone without a supervised transition to a shorter-acting opioid. Most antipsychotics. Severe liver or kidney disease. Active psychosis or schizophrenia-spectrum disorder. Pregnancy.

Someone in acute psychiatric crisis — active suicidality, recent hospitalisation, active psychotic episode — is not an appropriate candidate at this time, regardless of how long they have been searching for something that works. The experience amplifies what is present. Entering it in a state of acute destabilisation does not produce stabilisation.

Some contraindications are permanent. Some are preparation timelines — a supervised medication taper, a period of stabilisation first. The screening conversation is where that distinction is made for a specific individual. We tell people when they are not appropriate candidates — directly, without softening it.

Is This Right for You?

The starting point is a screening conversation, not a ceremony date.

Every application to Transcend receives a personal response within 2–3 business days. No ceremony date is confirmed before medical screening establishes candidacy: EKG, blood panel, medication review, and psychiatric history. These are not bureaucratic formalities — they are how the conditions that make ibogaine dangerous for a specific individual are identified before ceremony, not during it.

Iboga ceremony in Vancouver costs $2,000–$5,000 CAD. This covers an on-site medical professional for the full 12–24 hour active experience, continuous cardiac monitoring, whole-plant root bark, facilitation, and a 2–3 day supervised recovery period. Integration coaching — $150–$300 CAD per session, with packages of three or more sessions available — is a separate service. It is the part most directly responsible for whether the neuroplasticity window produces lasting change.

People who arrive at this work after exhausting the other options — with evidence that the first-resort treatments were not sufficient — tend to get more from ceremony than people who arrive expecting it to be straightforward. The medicine requires something of you. The ceremony page covers the full programme. The FAQ covers the most common screening questions. Or reach out directly.

Frequently Asked Questions

How does ibogaine work on opioid withdrawal specifically?: Ibogaine acts as a partial agonist at the mu-opioid receptor — the same receptor opioids bind to. This interrupts the physical withdrawal process within hours, rather than allowing it to build over days. At the same time, GDNF upregulation begins restoring dopamine pathway function depleted by long-term opioid use. The physical cravings associated with dependence are typically absent or substantially reduced in the days after ceremony. This is a different mechanism from substitution therapies like methadone or buprenorphine. Methadone specifically is an absolute contraindication for ibogaine and requires a supervised transition protocol before any ceremony date can be set.
What is the difference between ibogaine and noribogaine?: Ibogaine is the primary alkaloid from Tabernanthe ibogaroot bark — the compound that produces the 12–24 hour active experience. Noribogaine is ibogaine's main active metabolite, produced as ibogaine is processed by the liver. Noribogaine remains pharmacologically active for weeks to months after ceremony, producing a sustained anxiolytic and neuroplastic effect without the psychedelic intensity of the parent compound. This extended metabolite activity is the mechanism behind ibogaine's long-term effects — the window during which integration work has the most leverage.
How is ibogaine administered at a legitimate ceremony?: Oral administration — typically as whole-plant root bark containing ibogaine plus additional alkaloids, or as isolated ibogaine HCl. A legitimate programme includes pre-ceremony medical screening completed and reviewed before any ceremony date is set, a physician physically present on-site for the full duration of the active experience, continuous cardiac ECG monitoring throughout, and a supervised 2–3 day recovery period. A flood dose is the typical therapeutic administration — given once, not repeatedly. Dosing is weight-adjusted and determined by the medical team based on screening results.
Does ibogaine work for people who haven't tried other treatments first?: This is not the first question to ask. The first question is whether a specific person is medically appropriate — which requires screening before any consideration of sequencing. That said, the population with the strongest clinical evidence is treatment-resistant: people for whom conventional approaches were not sufficient. Someone seeking ibogaine as a first-line treatment for a condition that has not been evaluated or treated conventionally is unlikely to be an appropriate candidate at this point. The intake conversation is where this is determined for a specific individual.
What medications cannot be combined with ibogaine?: Absolute contraindications include: SSRIs and SNRIs (serotonin syndrome risk — real and potentially fatal, no exceptions); lithium; methadone without a supervised transition protocol; most antipsychotics; prescription MAOIs; tramadol. SSRIs require a physician-supervised taper completed before ceremony — typically 2–4 weeks, longer for medications with extended half-lives such as fluoxetine. These are hard contraindications, not cautions to weigh against potential benefit. A complete medication review is a required part of pre-ceremony screening.
What does ibogaine do to your brain long-term?: The long-term neurological research is ongoing. GDNF upregulation from a single ibogaine ceremony appears to produce durable restoration in dopamine pathway function — the proposed mechanism for sustained addiction remission. Noribogaine sustains elevated neuroplasticity for weeks to months. What is consistently observed in practice is that one-year outcomes depend heavily on what was done during the weeks following ceremony — the window that noribogaine creates is not self-executing. Structured integration work during that period produces consistently better outcomes than returning to an unchanged environment without support.
Who should not take ibogaine?: Absolute contraindications: QT prolongation or significant cardiac arrhythmia on EKG; recent myocardial infarction; current SSRIs or SNRIs without a completed physician-supervised taper (potentially fatal serotonin syndrome risk — no exceptions); lithium; methadone without a completed transition protocol; most antipsychotics; severe liver or kidney disease; active psychosis or schizophrenia-spectrum disorder; and pregnancy. Someone in acute psychiatric crisis — active suicidality, active psychosis, recent psychiatric hospitalisation — is not an appropriate candidate at this time regardless of how long they have been searching for something that works.
Is ibogaine's mechanism fully understood by science?: No. The receptor binding profile — mu-opioid partial agonism, serotonin transporter inhibition, NMDA antagonism, GDNF upregulation — is well-documented. How these mechanisms interact to produce the specific outcomes the Stanford study recorded is an active area of research. The $50 million committed to clinical trials at four Texas institutions is partly aimed at answering this. An incompletely understood mechanism does not change the clinical findings: 88% PTSD symptom reductions at one month in 30 treatment-resistant veterans are not explained by placebo, regardless of how precisely the mechanism is mapped.